A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

CRISPR

Section: Biopharma Insights     View all sections


A Race For Better Gene Editing Tech Is On

   by Irina Bilous    1122
A Race For Better Gene Editing Tech Is On

A transformative technology for gene editing - clustered regularly interspaced short palindromic repeats (CRISPR) -- has become ubiquitous, at least in research laboratories, where scientists efficiently adopted CRISPR technology to manipulate genes of interest. Still, applying it for humans is associated with greater risks and faces ethical issues. However, alongside a too reckless experiment of a Chinese scientist who edited babies’ genomes, plenty of companies have made well-thought progress toward transferring gene editing technologies into the clinic. Here we make a brief but pithy review on up-to-date gene editing approaches and start-up companies active in this area.

8 Biopharma Trends and Top Startups to Follow in 2017

   by Andrii Buvailo    10561
8 Biopharma Trends and Top Startups to Follow in 2017

Pharmaceutical industry is rapidly evolving, influenced by emerging novel technologies and recent advances in Life Sciences and Big Data analysis, new government policies and regulations, and a changing market conjuncture.

Let’s review some of the most powerful trends that will dominate the industry in 2017 and promising biopharmaceutical startups riding their waves.

Facebook and Napster founder Sean Parker is going to “hack cancer” by CRISPR technology

   by Andrii Buvailo    2303
Facebook and Napster founder Sean Parker is going to “hack cancer” by CRISPR technology

A billionaire Sean Parker, known as a founder of Facebook and Napster, has steeply entered Life Sciences industry to fund the world’s first-ever CRISPR/Cas9 trial, backed by US federal authorities. Upon success, the probability of which is now hard to assess, this technology can revolutionize the way cancer and many other diseases are treated. This time, Sean Parker is playing a bigger game than ever, however, uncertainty is huge.